|Bid||13.02 x 154300|
|Ask||13.04 x 392000|
|Day's range||12.92 - 13.09|
|52-week range||8.50 - 14.49|
|PE ratio (TTM)||43.40|
|Earnings date||20 Nov 2017 - 24 Nov 2017|
|Forward dividend & yield||0.23 (2.77%)|
|1y target est||12.35|
Fisher & Paykel Healthcare has won a patent case against rival medical products manufacturer ResMed, after a court in the United Kingdom ruled the patent claim invalid. In 2016, New Zealand-based Fisher & Paykel sought a declaration from the High Court that three of ResMed's European patents were invalid in the UK and should be revoked. ResMed revoked two of its patents in the UK just before the trial was due to start, but left one for consideration by the High Court's patents division.
A former Fisher & Paykel employee has admitted to corruption-related charges after receiving $213,000 in payments from Middle Eastern companies.